文献速递神经核医学肿瘤 PET/CT

多示踪剂活体PET/MRI探究CSF-1R治疗下胶质瘤相关小胶质细胞与巨噬细胞的动态变化

Interrogating Glioma-Associated Microglia and Macrophage Dynamics Under CSF-1R Therapy with Multitracer In Vivo PET/MRI.
PubMed 文献 · J Nucl Med · 2022-02-03

研究用C57BL/6小鼠原位植入GL261胶质瘤细胞(n=44),以CSF-1R抑制剂PLX5622或溶媒处理,建立预处理模型与再填充模型,行纵向18F-FET与18F-DPA-714 PET/CT及PET/MRI。预处理模型各组肿瘤生长相似,提示GAMMs不参与胶质瘤起始;再填充模型18F-DPA-714摄取降低45.6%±18.4%、MRI肿瘤体积降低54.29%±8.6%、18F-FET摄取降低50.2%±5.3%。作者认为CSF-1R介导的GAMMs调节可能作为胶质瘤治疗或联合治疗方向。

要点

  • 预处理模型各组MRI、18F-FET PET、18F-DPA-714 PET体积动态相似,提示GAMMs不参与胶质瘤起始。
  • 再填充模型18F-DPA-714摄取降低45.6%±18.4%,再填充后GAMM浸润仍显著减少。
  • 再填充模型MRI肿瘤体积降低54.29%±8.6%,18F-FET摄取降低50.2%±5.3%。

核心结论

  • 18F-FET与18F-DPA-714 PET/MRI可无创评估CSF-1R不同治疗方案下的胶质瘤生长。
  • CSF-1R介导的GAMMs调节可能作为胶质瘤治疗或联合治疗的高关注方向。

研究设计与样本

  • C57BL/6小鼠(n=44)原位植入同系小鼠GL261胶质瘤细胞。
  • 小鼠分别接受CSF-1R抑制剂PLX5622不同方案或溶媒处理,建立预处理模型与再填充模型。
  • 小鼠接受纵向PET/CT与PET/MRI,示踪剂为18F-FET(氨基酸代谢)与18F-DPA-714(转位蛋白)。

主要发现

  • 预处理模型各组基于MRI(44.5%±24.8%)、18F-FET PET(18.3%±11.3%)与18F-DPA-714 PET(16%±19.04%)的体积动态相似,提示GAMMs不参与胶质瘤起始。
  • 再填充模型18F-DPA-714摄取显著降低(-45.6%±18.4%),再填充后GAMM浸润仍显著减少。
  • 再填充模型MRI测得肿瘤体积显著降低(-54.29%±8.6%)。
  • 再填充模型18F-FET摄取显著降低(-50.2%±5.3%),支持MRI体积结果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Glioma-associated microglia and macrophages (GAMMs) are key players in creating an immunosuppressive microenvironment. They can be efficiently targeted by inhibiting the colony-stimulating factor 1 receptor (CSF-1R). We applied noninvasive PET/CT and PET/MRI using 18F-fluoroethyltyrosine (18F-FET) (amino acid metabolism) and N,N-diethyl-2-[4-(2-18F-fluoroethoxy)phenyl]-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-acetamide (18F-DPA-714) (translocator protein) to understand the role of GAMMs in glioma initiation, monitor in vivo therapy-induced GAMM depletion, and observe GAMM repopulation after drug withdrawal. Methods: C57BL/6 mice (n = 44) orthotopically implanted with syngeneic mouse GL261 glioma cells were treated with different regimens using the CSF-1R inhibitor PLX5622 (6-fluoro-N-((5-fluoro-2-methoxypyridin-3-yl)methyl)-5-((5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl)pyridin-2-amine) or vehicle, establishing a preconditioning model and a repopulation model, respectively. The mice underwent longitudinal PET/CT and PET/MRI. Results: The preconditioning model indicated similar tumor growth based on MRI (44.5% ± 24.8%), 18F-FET PET (18.3% ± 11.3%), and 18F-DPA-714 PET (16% ± 19.04%) volume dynamics in all groups, suggesting that GAMMs are not involved in glioma initiation. The repopulation model showed significantly reduced 18F-DPA-714 uptake (-45.6% ± 18.4%), significantly reduced GAMM infiltration even after repopulation, and a significantly decreased tumor volume (-54.29% ± 8.6%) with repopulation as measured by MRI, supported by a significant reduction in 18F-FET uptake (-50.2% ± 5.3%). Conclusion: 18F-FET and 18F-DPA-714 PET/MRI allow noninvasive assessment of glioma growth under various regimens of CSF-1R therapy. CSF-1R-mediated modulation of GAMMs may be of high interest as therapy or cotherapy against glioma.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Foray C, Barca C, Winkeler A, et al. Interrogating Glioma-Associated Microglia and Macrophage Dynamics Under CSF-1R Therapy with Multitracer In Vivo PET/MRI. J Nucl Med. 2022. PMID: 35115369. doi:10.2967/jnumed.121.263318

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。